Letter of intent requirements
Letters of intent are due by Friday, March 15, 2013, for the 2013 NMDA and should be submitted via email to email@example.com. The letter should describe the methodological development envisioned, its potential for use by other Mayo investigators, and the feasibility of rapid implementation of this advance in research and/or clinical practice. It should be up to two pages in length and include:
- Title and summary page (one-page limit)
- Name of principal investigator
- Principal investigator's department/division
- Names of all other participating investigators and their department/division and site
- Project title
- Project summary (200 words)
- Responsiveness and deliverables (one page limit)
- Statement on how project meets program intent
- Specific deliverables
Full application requirements
After letters of intent are reviewed, those applicants chosen to submit full applications will be formally notified, with a final application deadline of Monday, May 13, 2013. If you are invited to submit a full application, the Novel Methodology Development Award (NMDA) checklist will guide you through the process.
This checklist details the components of a complete application and includes instructions and downloadable templates for your protocol and budget. Closely follow the budget instructions.
Reviews will be conducted by the CTSA Novel Methodology Review Panel in accordance with its procedures to generate a NIH-style score (1-5). Review criteria include:
- Scientific merit, including significance, innovation and potential impact
- Feasibility with the time and budget proposed
- Qualifications of the investigators
- Breadth of applicability to a variety of clinical and translational research endeavors
- Potential for immediate dissemination to the clinical research community
- Amount of funding requested
- Potential to result in new or renewed grant funding
- Development of the method within one year
- Beneficial to a variety of investigators
- Potential for publication of results
The Review Panel also encourages opportunities for cost sharing with departments/divisions. Based upon the Review Panel's recommendations, final funding decisions will be made by the CTSA Executive Committee, which will also consider available funds and CTSA priorities.
Resubmission of applications
Applications not funded by the CTSA Scientific Review Panel may be resubmitted for consideration one time. Resubmission of previously unfunded protocols does not require department/division research committee approval unless requested by the CTSA Scientific Review Panel. When conducting the review process, the CTSA Scientific Review Panel will give consideration to opportunities for cost sharing with departments and divisions.
A final report will be required at the end of the funding period, and should include a description of the arrangements made for use of the new methodology by other Mayo investigators.
The NIH Public Access Policy requires that all publications resulting from NIH funding be uploaded to PubMed Central. CTSA awards, including intramurally funded awards, must follow this policy. The Mayo Clinic Public Access Policy intranet site (requires that you be logged in to the Mayo network) will guide awardees through the process of uploading publications.
Please remember to cite the Mayo Clinic CTSA in your publication:
This publication was made possible by the Mayo Clinic CTSA through grant number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH).